Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.

Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen-Lindsberg ML, Mannisto S, Kellokumpu-Lehtinen PL, Kallioniemi O, Mustjoki S, Leppä S.

Haematologica. 2018 Sep 20. pii: haematol.2018.200105. doi: 10.3324/haematol.2018.200105. [Epub ahead of print]

2.

PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.

Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg ML, Mannisto S, Kallioniemi O, Kellokumpu-Lehtinen PL, Mustjoki S, Leivonen SK, Leppä S.

Haematologica. 2018 Nov;103(11):1908-1914. doi: 10.3324/haematol.2018.197194. Epub 2018 Jul 19.

3.

R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma.

Prusila REI, Haapasaari KM, Marin K, Pollari M, Soini Y, Vornanen M, Karjalainen-Lindsberg ML, Turpeenniemi-Hujanen T, Kuittinen O.

Acta Oncol. 2018 Sep;57(9):1265-1267. doi: 10.1080/0284186X.2018.1450522. Epub 2018 Mar 14. No abstract available.

PMID:
29537344
4.

MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma.

Leivonen SK, Icay K, Jäntti K, Siren I, Liu C, Alkodsi A, Cervera A, Ludvigsen M, Hamilton-Dutoit SJ, d'Amore F, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S.

Blood Cancer J. 2017 Dec 15;7(12):654. doi: 10.1038/s41408-017-0033-8.

5.

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS.

Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.

6.

Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

Leivonen SK, Taskinen M, Cervera A, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S.

Blood Cancer J. 2017 Aug 25;7(8):e596. doi: 10.1038/bcj.2017.71.

7.

Breast implant-associated anaplastic large cell lymphoma - From diagnosis to treatment.

Kaartinen I, Sunela K, Alanko J, Hukkinen K, Karjalainen-Lindsberg ML, Svarvar C.

Eur J Surg Oncol. 2017 Aug;43(8):1385-1392. doi: 10.1016/j.ejso.2017.05.021. Epub 2017 Jun 7. Review.

PMID:
28625797
8.

Clinical findings in 25 patients with sinonasal or nasopharyngeal extramedullary plasmacytoma in a four-decade single-centre series.

Vento SI, Vähämurto P, Silventoinen K, Karjalainen-Lindsberg ML, Mannisto S, Leppä S, Mäkitie AA.

Acta Otolaryngol. 2017 Sep;137(9):975-980. doi: 10.1080/00016489.2017.1325514. Epub 2017 May 24.

PMID:
28537101
9.

TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma.

Schwartz FH, Cai Q, Fellmann E, Hartmann S, Mäyränpää MI, Karjalainen-Lindsberg ML, Sundström C, Scholtysik R, Hansmann ML, Küppers R.

J Pathol. 2017 Jun;242(2):129-133. doi: 10.1002/path.4898. Epub 2017 May 3.

PMID:
28337768
10.

Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma.

Meriranta L, Pasanen A, Louhimo R, Cervera A, Alkodsi A, Autio M, Taskinen M, Rantanen V, Karjalainen-Lindsberg ML, Holte H, Delabie J, Lehtonen R, Hautaniemi S, Leppä S.

Haematologica. 2017 May;102(5):e195-e198. doi: 10.3324/haematol.2016.157495. Epub 2017 Feb 9. No abstract available.

11.

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH; Nordic Lymphoma Group.

Biol Blood Marrow Transplant. 2017 Mar;23(3):428-435. doi: 10.1016/j.bbmt.2016.12.634. Epub 2016 Dec 27.

12.

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH.

Br J Haematol. 2016 Nov;175(3):410-418. doi: 10.1111/bjh.14241. Epub 2016 Jul 5.

PMID:
27378674
13.

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Grønbæk K, Sundberg J, Pedersen LB, Ralfkiær E, Karjalainen-Lindsberg ML, Sundström C, Ehinger M, Geisler C, Jerkeman M.

Blood. 2016 Oct 6;128(14):1814-1820. doi: 10.1182/blood-2016-03-704023. Epub 2016 Jun 27.

14.

Clinical findings of extranodal SNT lymphoid malignancies in a four-decade single-centre series.

Vähämurto P, Silventoinen K, Vento SI, Karjalainen-Lindsberg ML, Haapaniemi A, Bäck L, Mannisto S, Leppä S, Mäkitie AA.

Eur Arch Otorhinolaryngol. 2016 Nov;273(11):3839-3845. Epub 2016 Mar 24.

PMID:
27010643
15.

Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma.

Peroja P, Haapasaari KM, Mannisto S, Miinalainen I, Koivunen P, Leppä S, Karjalainen-Lindsberg ML, Kuusisto ME, Turpeenniemi-Hujanen T, Kuittinen O, Karihtala P.

Virchows Arch. 2016 May;468(5):623-30. doi: 10.1007/s00428-016-1920-2. Epub 2016 Mar 16.

PMID:
26983700
16.

Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.

Harjama L, Kuitunen H, Turpeenniemi-Hujanen T, Haapasaari KM, Leppä S, Mannisto S, Karjalainen-Lindsberg ML, Lehtinen T, Eray M, Vornanen M, Haapasalo H, Soini Y, Jantunen E, Nousiainen T, Vasala K, Kuittinen O.

Acta Oncol. 2015 Jun;54(6):939-43. doi: 10.3109/0284186X.2014.990110. Epub 2015 Mar 11.

PMID:
25761092
17.

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.

Husby S, Ralfkiaer U, Garde C, Zandi R, Ek S, Kolstad A, Jerkeman M, Laurell A, Räty R, Pedersen LB, Pedersen A, Ehinger M, Sundström C, Karjalainen-Lindsberg ML, Delabie J, Clasen-Linde E, Brown P, Cowland JB, Workman CT, Geisler CH, Grønbæk K.

Blood. 2015 Apr 23;125(17):2669-77. doi: 10.1182/blood-2014-06-584193. Epub 2015 Mar 3.

18.

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.

Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppä S.

Haematologica. 2015 Feb;100(2):238-45. doi: 10.3324/haematol.2014.113472. Epub 2014 Nov 7.

19.

Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.

Haapaniemi EM, Kaustio M, Rajala HL, van Adrichem AJ, Kainulainen L, Glumoff V, Doffinger R, Kuusanmäki H, Heiskanen-Kosma T, Trotta L, Chiang S, Kulmala P, Eldfors S, Katainen R, Siitonen S, Karjalainen-Lindsberg ML, Kovanen PE, Otonkoski T, Porkka K, Heiskanen K, Hänninen A, Bryceson YT, Uusitalo-Seppälä R, Saarela J, Seppänen M, Mustjoki S, Kere J.

Blood. 2015 Jan 22;125(4):639-48. doi: 10.1182/blood-2014-04-570101. Epub 2014 Oct 27.

20.

Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H.

Leuk Lymphoma. 2015 Jun;56(6):1742-9. doi: 10.3109/10428194.2014.970550. Epub 2014 Nov 19.

PMID:
25284491
21.

[Esophageal varices and dyspnea. A clinicopathological conference report].

Heikkinen M, Västrik R, Karjalainen-Lindsberg ML, Pohjola-Sintonen S.

Duodecim. 2014;130(7):706-13. Finnish.

PMID:
24772788
22.

[Febrile episodes of unknown origin, elevated level of plasma ferritin and rapidly developed multiorgan dysfunction].

Jantunen E, Siitonen S, Karjalainen-Lindsberg ML.

Duodecim. 2014;130(3):269-77. Finnish.

PMID:
24660387
23.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N, Geisler CH; Nordic Lymphoma Group.

Blood. 2014 May 8;123(19):2953-9. doi: 10.1182/blood-2013-12-541953. Epub 2014 Mar 20.

24.

Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.

Taskinen M, Louhimo R, Koivula S, Chen P, Rantanen V, Holte H, Delabie J, Karjalainen-Lindsberg ML, Björkholm M, Fluge Ø, Pedersen LM, Fjordén K, Jerkeman M, Eriksson M, Hautaniemi S, Leppä S.

PLoS One. 2014 Mar 13;9(3):e91031. doi: 10.1371/journal.pone.0091031. eCollection 2014.

25.

Genetic variation in schlafen genes in a patient with a recapitulation of the murine Elektra phenotype.

Recher M, Karjalainen-Lindsberg ML, Lindlöf M, Söderlund-Venermo M, Lanzi G, Väisänen E, Kumar A, Sadeghi M, Berger CT, Alitalo T, Anttila P, Kolehmainen M, Franssila R, Chen T, Siitonen S, Delmonte OM, Walter JE, Pessach I, Hess C, Simpson MA, Navarini AA, Giliani S, Hedman K, Seppänen M, Notarangelo LD.

J Allergy Clin Immunol. 2014 May;133(5):1462-5, 1465.e1-5. doi: 10.1016/j.jaci.2013.10.052. Epub 2013 Dec 24. No abstract available.

PMID:
24373355
26.

MicroRNA profiling in chemoresistant and chemosensitive acute myeloid leukemia.

Mosakhani N, Räty R, Tyybäkinoja A, Karjalainen-Lindsberg ML, Elonen E, Knuutila S.

Cytogenet Genome Res. 2013;141(4):272-6. doi: 10.1159/000351219. Epub 2013 May 16.

PMID:
23689423
27.

Primary mediastinal large B-cell lymphoma segregating in a family: exome sequencing identifies MLL as a candidate predisposition gene.

Saarinen S, Kaasinen E, Karjalainen-Lindsberg ML, Vesanen K, Aavikko M, Katainen R, Taskinen M, Kytölä S, Leppä S, Hietala M, Vahteristo P, Aaltonen LA.

Blood. 2013 Apr 25;121(17):3428-30. doi: 10.1182/blood-2012-06-437210. Epub 2013 Mar 1.

28.

[Thirst and extensive bone lesions in a previously basically healthy woman].

Laitinen K, Lamminen A, Anttila P, Lohman M, Karjalainen-Lindsberg ML.

Duodecim. 2012;128(22):2355-64. Finnish.

PMID:
23342482
29.

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M.

Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17.

PMID:
23247661
30.

MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.

Mosakhani N, Lahti L, Borze I, Karjalainen-Lindsberg ML, Sundström J, Ristamäki R, Osterlund P, Knuutila S, Sarhadi VK.

Cancer Genet. 2012 Nov;205(11):545-51. doi: 10.1016/j.cancergen.2012.08.003. Epub 2012 Oct 23.

PMID:
23098991
31.

Combating cancer predisposition in association with idiopathic immune deficiency: a recurrent nodal and cutaneous T-cell lymphoproliferative disease in a patient with cartilage-hair hypoplasia.

Taskinen M, Jeskanen L, Karjalainen-Lindsberg ML, Mäkitie A, Mäkitie O, Ranki A.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):73-6. doi: 10.1016/j.clml.2012.06.005. Epub 2012 Sep 20. No abstract available.

PMID:
22999941
32.

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group.

Br J Haematol. 2012 Aug;158(3):355-62. doi: 10.1111/j.1365-2141.2012.09174.x. Epub 2012 May 29. Erratum in: Br J Haematol. 2012 Sep;158(6):815-6.

PMID:
22640180
33.

MicroRNA profiling in pediatric acute lymphoblastic leukemia: novel prognostic tools.

Mosakhani N, Sarhadi VK, Usvasalo A, Karjalainen-Lindsberg ML, Lahti L, Tuononen K, Saarinen-Pihkala UM, Knuutila S.

Leuk Lymphoma. 2012 Dec;53(12):2517-20. doi: 10.3109/10428194.2012.685731. Epub 2012 May 22. No abstract available.

PMID:
22506670
34.

Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.

Räty R, Honkanen T, Jantunen E, Jyrkkiö S, Karjalainen-Lindsberg ML, Kuittinen O, Lehto M, Mikkola M, Poikonen E, Rauhala A, Rimpiläinen J, Räsänen A, Siitonen S, Suominen M, Vapaatalo M, Elonen E.

Leuk Lymphoma. 2012 Oct;53(10):1920-8. doi: 10.3109/10428194.2012.672736. Epub 2012 Apr 23.

PMID:
22397313
35.

MicroRNA profiling differentiates colorectal cancer according to KRAS status.

Mosakhani N, Sarhadi VK, Borze I, Karjalainen-Lindsberg ML, Sundström J, Ristamäki R, Osterlund P, Knuutila S.

Genes Chromosomes Cancer. 2012 Jan;51(1):1-9. doi: 10.1002/gcc.20925. Epub 2011 Sep 15.

PMID:
21922590
36.

Comparison of in vitro breast cancer visibility in analyser-based computed tomography with histopathology, mammography, computed tomography and magnetic resonance imaging.

Keyriläinen J, Fernández M, Bravin A, Karjalainen-Lindsberg ML, Leidenius M, von Smitten K, Tenhunen M, Kangasmäki A, Sipilä P, Nemoz C, Virkkunen P, Suortti P.

J Synchrotron Radiat. 2011 Sep;18(Pt 5):689-96. doi: 10.1107/S090904951102810X. Epub 2011 Jul 26.

PMID:
21862846
37.

Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project.

Marcos-Gragera R, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Maynadie M, Luminari S, Ferretti S, Johannesen TB, Sankila R, Karjalainen-Lindsberg ML, Simonetti A, Martos MC, Raphaël M, Giraldo P, Sant M; HAEMACARE Working Group.

Haematologica. 2011 May;96(5):720-8. doi: 10.3324/haematol.2010.034264. Epub 2011 Feb 17.

38.

MicroRNA microarrays on archive bone marrow core biopsies of leukemias--method validation.

Borze I, Guled M, Musse S, Raunio A, Elonen E, Saarinen-Pihkala U, Karjalainen-Lindsberg ML, Lahti L, Knuutila S.

Leuk Res. 2011 Feb;35(2):188-95. doi: 10.1016/j.leukres.2010.08.005. Epub 2010 Sep 9.

PMID:
20828815
39.

Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy.

Taskinen M, Jantunen E, Kosma VM, Bono P, Karjalainen-Lindsberg ML, Leppä S.

Eur J Cancer. 2010 Sep;46(13):2506-12. doi: 10.1016/j.ejca.2010.06.014. Epub 2010 Jul 12.

PMID:
20630741
40.

Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.

Taskinen M, Valo E, Karjalainen-Lindsberg ML, Hautaniemi S, Meri S, Leppä S.

Clin Cancer Res. 2010 May 1;16(9):2615-23. doi: 10.1158/1078-0432.CCR-09-3269. Epub 2010 Apr 13.

41.

Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines.

Junnila S, Kokkola A, Karjalainen-Lindsberg ML, Puolakkainen P, Monni O.

BMC Cancer. 2010 Mar 1;10:73. doi: 10.1186/1471-2407-10-73.

42.

Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage.

Lindsberg PJ, Strbian D, Karjalainen-Lindsberg ML.

J Cereb Blood Flow Metab. 2010 Apr;30(4):689-702. doi: 10.1038/jcbfm.2009.282. Epub 2010 Jan 20. Review.

43.

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group.

Blood. 2010 Feb 25;115(8):1530-3. doi: 10.1182/blood-2009-08-236570. Epub 2009 Dec 23.

44.

Tumour microvessel endothelial cell KIT and stem cell factor expression in human solid tumours.

Sihto H, Tynninen O, Halonen M, Puputti M, Karjalainen-Lindsberg ML, Kukko H, Joensuu H.

Histopathology. 2009 Nov;55(5):544-53. doi: 10.1111/j.1365-2559.2009.03418.x.

PMID:
19912360
45.

Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer.

Junnila S, Kokkola A, Mizuguchi T, Hirata K, Karjalainen-Lindsberg ML, Puolakkainen P, Monni O.

Genes Chromosomes Cancer. 2010 Jan;49(1):28-39. doi: 10.1002/gcc.20715.

PMID:
19780053
46.

Neuronal caspase-3 and PARP-1 correlate differentially with apoptosis and necrosis in ischemic human stroke.

Sairanen T, Szepesi R, Karjalainen-Lindsberg ML, Saksi J, Paetau A, Lindsberg PJ.

Acta Neuropathol. 2009 Oct;118(4):541-52. doi: 10.1007/s00401-009-0559-3. Epub 2009 Jun 16.

PMID:
19529948
47.

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.

Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Leppä S.

Mod Pathol. 2009 Aug;22(8):1094-101. doi: 10.1038/modpathol.2009.73. Epub 2009 May 15.

48.

An emerging role of mast cells in cerebral ischemia and hemorrhage.

Strbian D, Kovanen PT, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ.

Ann Med. 2009;41(6):438-50. doi: 10.1080/07853890902887303. Review.

PMID:
19412821
49.

[Is lymphoma curable with antibody therapy?].

Leppä S, Nyman H, Karjalainen-Lindsberg ML.

Duodecim. 2009;125(3):267-73. Finnish.

PMID:
19341039
50.

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.

Eur J Haematol. 2009 May;82(5):364-72. doi: 10.1111/j.1600-0609.2009.01222.x. Epub 2009 Jan 9.

PMID:
19141121

Supplemental Content

Loading ...
Support Center